2-(5-chloro-6-trifluoromethyl-1H-indol-2-yl)-1-(4-fluoro-phenylsulfanyl)-propan-2-ol | 868690-39-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(5-chloro-6-trifluoromethyl-1H-indol-2-yl)-1-(4-fluoro-phenylsulfanyl)-propan-2-ol
• 英文别名: 2-(5-chloro-6-(trifluoromethyl)-1H-indol-2-yl)-1-(4-fluorophenylthio)propan-2-ol；2-[5-chloro-6-(trifluoromethyl)-1H-indol-2-yl]-1-(4-fluorophenyl)sulfanylpropan-2-ol
• CAS: 868690-39-5
• 化学式: C₁₈H₁₄ClF₄NOS
• 分子量: 403.828
• InChiKey: CRPQTBRTHURKII-UHFFFAOYSA-N

物化性质

• 沸点：
  538.4±50.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(5-chloro-6-trifluoromethyl-1H-indol-2-yl)-1-(4-fluoro-phenylsulfanyl)-propan-2-ol 在 四丁基硫酸氢铵 Oxone 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 2-(5-Chloro-6-trifluoromethyl-1H-indol-2-yl)-1-(4-fluoro-benzenesulfonyl)-propan-2-ol
  参考文献：
  名称：

  Novel indole derivatives as selective androgen receptor modulators (SARMS)

  摘要：

  本发明涉及新型吲哚衍生物，含有它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。

  公开号：

  US20050250741A1
• 作为产物：
  描述：

  N-(4-chloro-2-iodo-5-trifluoromethyl-phenyl)-methanesulfonamide 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 sodium methylate 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 2-(5-chloro-6-trifluoromethyl-1H-indol-2-yl)-1-(4-fluoro-phenylsulfanyl)-propan-2-ol
  参考文献：
  名称：

  A bioisosteric approach to the discovery of indole carbinol androgen receptor ligands

  摘要：

  Two potential bioisosteres of the nonsteroidal antiandrogen bicalutamide, an imidazolidinone and an indole, were synthesized and tested for their androgen receptor binding. Indole was discovered to be a suitable bioisostere for the acyl anilide moiety in the parent compound. Several analogs in the indole series were found to be 10-fold better than bicalutamide in binding to the recombinant androgen receptor binding domain. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.036

文献信息

• Novel indole derivatives as selective androgen receptor modulator (SARMS)
  申请人：Lanter C. James

  公开号：US20050250740A1

  公开（公告）日：2005-11-10

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物，含有它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
• NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
  申请人：Lanter James C.

  公开号：US20090216023A1

  公开（公告）日：2009-08-27

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物，包含它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
• Indole derivatives as selective androgen receptor modulators (SARMS)
  申请人：Janssen Pharmaceutica N.V.

  公开号：US07282507B2

  公开（公告）日：2007-10-16

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新颖的吲哚衍生物、包含它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。
• Indole derivatives as selective androgen receptor modulators (sarms)
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP2078712A1

  公开（公告）日：2009-07-15

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物、含有这些衍生物的药物组合物及其在治疗受雄激素受体调节的紊乱和病症中的用途。
• MEDICINAL COMPOSITION FOR INHIBITING AMYLOID- PROTEIN DEPOSITION
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP2246334A1

  公开（公告）日：2010-11-03

  The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on.

  本发明提供了：一种用于抑制淀粉样蛋白-β蛋白积累的药物组合物，该组合物包含作为活性成分的式(I)化合物或其药学上可接受的盐；一种抑制淀粉样蛋白-β蛋白积累的方法，该方法包括向可能被诊断患有淀粉样蛋白-β蛋白相关疾病的哺乳动物施用有效量的式(I)化合物或其药学上可接受的盐的步骤；等等。